The Beauty Health Company (SKIN) AI Stock Analysis

The Beauty Health Company designs, manufactures, and markets aesthetic technologies and products focused on skin health and beauty. Its flagship offering is HydraFacial, a treatment system that cleanses, peels, exfoliates, extracts, infuses, and hydrates skin with proprietary solutions and serums. The company also provides Syndeo, an advanced delivery system that integrates with HydraFacial treatments to personalize skincare by linking healthcare providers with consumer preferences. Additionally, it offers Keravive for scalp health and the HydraFacial Nation App, which educates consumers, supports treatment discovery, and tracks individual skincare progress.

Revenue grew from $260.1M in FY2021 to a peak of $398.0M in FY2023 before contracting to $334.3M in FY2024 and $300.8M in FY2025. Gross margin fluctuated from 68.6% in FY2021 down to 39.0% in FY2023, then recovered to 65.3% in FY2025. Operating margin was -6.9% in FY2025, improving from -20.3% in FY2024. Net income improved from -$378.8M in FY2021 to -$9.5M in FY2025, with FY2022 being the only profitable year at $44.2M. For the latest quarter ended June 30, 2026, quarterly revenue fell 7.8% year-over-year, bringing trailing twelve-month revenue to $290.0M.

As of June 30, 2026, the company held $206.1M in cash and short-term investments against total debt of $367.1M, resulting in net debt of $161.0M. Shareholders' equity stood at $55.6M, yielding a debt-to-equity ratio of 6.60 and a current ratio of 1.76. Total assets totaled $486.6M. Operating cash flow reached $37.5M in FY2025, supporting free cash flow of $32.3M after capital expenditures of $5.2M. Over five years, the share count declined 95.6%.

At a share price of $10.56, The Beauty Health Company has a market cap of $68.7M and an enterprise value of $248.6M. The stock trades at a forward P/E of 106.4x, well above the 14.3x median of its US-listed Consumer Defensive peers. Its price-to-sales ratio is 0.2x and EV-to-EBITDA is 9.6x, compared to sector peer medians of 0.7x and 11.7x, respectively. Over the trailing year, the stock dropped 63.3%, lagging the S&P 500 benchmark return of 16.8%, and is down 97.9% over five years.

Wall Street analysts display a consensus rating breakdown of 1 Strong Buy, 6 Holds, and 2 Sells. The mean price target is $18.17, representing an upside of 72.0% from the October 16, 2026 closing price of $10.56. For the fiscal year ending December 31, 2026, analysts estimate an EPS of $2.56 on revenue of $285.1M. The company beat EPS estimates in 3 of the last 4 quarters. The next earnings date is scheduled for November 5, 2026.

This page is an AI-written research summary of The Beauty Health Company (SKIN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SKIN income statement, SKIN balance sheet, SKIN key metrics, SKIN analyst forecast, SKIN chart. See the SKIN stock overview for the latest quote and news.